Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary R Cutter

Showing results (251-260 of 296) with videos related to

Pageof 30
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 2, 2012
Inflammation, apoptosis, and necrosis induced by neoadjuvant fas ligand gene therapy improves survival of dogs with spontaneous bone cancerJaime F Modiano, Donald Bellgrau, Gary R Cutter, et al.
Archives of Neurology|July 16, 2008
Retinal imaging by laser polarimetry and optical coherence tomography evidence of axonal degeneration in multiple sclerosisMaulik S Zaveri, Amy Conger, Amber Salter, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 23, 2022
Association of Vitamin D Polygenic Risk Scores and Disease Outcome in People With Multiple SclerosisEleni S Vasileiou, Chen Hu, Charles N Bernstein, et al.
Neurology and Therapy|July 24, 2024
Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri<sup>®</sup>) Dosing: NOVA Phase IIIb Extension Study (Part 2)Heinz Wiendl, John Foley, Gilles Defer, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 9, 2023
Improving the efficiency of clinical trials in multiple sclerosisRuth Ann Marrie, Maria Pia Sormani, Sean Apap Mangion, et al.
Multiple Sclerosis and Related Disorders|April 12, 2016
Relapses in multiple sclerosis: Relationship to disabilityDouglas S Goodin, Anthony T Reder, Robert A Bermel, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 11, 2024
Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple SclerosisJohn F Foley, Gilles Defer, Lana Zhovtis Ryerson, et al.
Neurology|February 17, 2019
The prevalence of MS in the United States: A population-based estimate using health claims dataMitchell T Wallin, William J Culpepper, Jonathan D Campbell, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 1, 2021
Cardiorespiratory fitness and free-living physical activity are not associated with cognition in persons with progressive multiple sclerosis: Baseline analyses from the CogEx studyBrian M Sandroff, Robert W Motl, Maria Pia Amato, et al.
Ophthalmology|January 13, 2006
Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosisJennifer B Fisher, Dina A Jacobs, Clyde E Markowitz, et al.
Pageof 30

Showing results (251-260 of 296) with videos related to

Sort By:
Pageof 30
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 2, 2012
Inflammation, apoptosis, and necrosis induced by neoadjuvant fas ligand gene therapy improves survival of dogs with spontaneous bone cancerJaime F Modiano, Donald Bellgrau, Gary R Cutter, et al.
Archives of Neurology|July 16, 2008
Retinal imaging by laser polarimetry and optical coherence tomography evidence of axonal degeneration in multiple sclerosisMaulik S Zaveri, Amy Conger, Amber Salter, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 23, 2022
Association of Vitamin D Polygenic Risk Scores and Disease Outcome in People With Multiple SclerosisEleni S Vasileiou, Chen Hu, Charles N Bernstein, et al.
Neurology and Therapy|July 24, 2024
Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri<sup>®</sup>) Dosing: NOVA Phase IIIb Extension Study (Part 2)Heinz Wiendl, John Foley, Gilles Defer, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 9, 2023
Improving the efficiency of clinical trials in multiple sclerosisRuth Ann Marrie, Maria Pia Sormani, Sean Apap Mangion, et al.
Multiple Sclerosis and Related Disorders|April 12, 2016
Relapses in multiple sclerosis: Relationship to disabilityDouglas S Goodin, Anthony T Reder, Robert A Bermel, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 11, 2024
Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple SclerosisJohn F Foley, Gilles Defer, Lana Zhovtis Ryerson, et al.
Neurology|February 17, 2019
The prevalence of MS in the United States: A population-based estimate using health claims dataMitchell T Wallin, William J Culpepper, Jonathan D Campbell, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 1, 2021
Cardiorespiratory fitness and free-living physical activity are not associated with cognition in persons with progressive multiple sclerosis: Baseline analyses from the CogEx studyBrian M Sandroff, Robert W Motl, Maria Pia Amato, et al.
Ophthalmology|January 13, 2006
Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosisJennifer B Fisher, Dina A Jacobs, Clyde E Markowitz, et al.
Pageof 30